HR+/HER2- breast cancer, with adjuvant CDK4/6 inhibitor risk of recurrence reduced by 28%

The ESMO Congress in Berlin provided important confirmation for the treatment of HR+/HER2-positive early-stage breast cancer. Five-year data from the NATALEE study were presented, which tested a CDK4/6 inhibitor in addition to endocrine therapy as an adjuvant treatment in this patient group. We discuss this in this interview with Professor Michelino De Laurentiis, Director of the Department of Breast and Thoracic-Pulmonary Oncology at the National Cancer Institute IRCCS Fondazione 'G. Pascale' in Naples.